

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beauty Farm Medical and Health Industry Inc.

美麗田園醫療健康產業有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2373)

- (1) COMPLETION OF DISPOSAL OF SHARES BY
SUBSTANTIAL SHAREHOLDER;**
- (2) RESIGNATION OF NON-EXECUTIVE DIRECTORS;**
- (3) APPOINTMENT OF NON-EXECUTIVE DIRECTORS; AND**
- (4) CHANGES IN COMPOSITION OF THE
REMUNERATION COMMITTEE**

COMPLETION OF DISPOSAL OF SHARES BY SUBSTANTIAL SHAREHOLDER

Reference is made to the announcement of Beauty Farm Medical and Health Industry Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated June 25, 2025 (the “**Announcement**”). The Company has been further informed by CITIC Private Equity Funds Management Co., Ltd. (“**CPE**”) that it has completed the disposal of the shares referenced in the Announcement, on August 18, 2025. As of August 18, 2025, CPE has disposed most of its shares in the Company through a series of transactions. CPE is no longer a substantial shareholder of the Company.

The exit of CPE provides critical support for the Company’s shareholder structure adjustment, unlocking multiple positive effects: first, the smooth exit of private equity fund shareholders has significantly enhanced the stability of the equity structure; second, the introduction of high-quality long-term investors with diverse backgrounds has further improved the corporate governance system, effectively boosting capital market confidence in the Company’s long-term value; third, the optimization of the equity structure has increased the proportion of tradable shares and enhanced market liquidity.

The Company has secured long-term, high-quality capital commitment from both domestic and international sources, and the addition of these new shareholders not only brings rich industrial resource synergy and an international perspective but also injects strategic experience and resource networks, adding new momentum to the Company’s business expansion and capital market value enhancement.

* *For identification purposes only*

As an early investor, CPE provided important strategic guidance during the Group's development and helped the Group successfully enter the capital market. The Company would like to express its sincere gratitude to CPE.

Upon the completion of the above disposal of shares by substantial shareholder, the board of directors (the "**Board**") of the Company announces the following changes of directors ("**Director(s)**") of the Company:

RESIGNATION OF NON-EXECUTIVE DIRECTORS

As CPE is no longer a substantial shareholder of the Company, Mr. HU Tenghe ("**Mr. Hu**") and Mr. GENG Jiaqi ("**Mr. Geng**") have decided to step down from their current positions as non-executive Directors, and have tendered their resignations on August 18, 2025 with effect on the same day. Both have confirmed that they have no disagreements with the Board, and there are no matters relating to their resignations that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to express its sincere gratitude to Mr. Hu and Mr. Geng for their valuable contributions during their tenure of office as non-executive Directors.

APPOINTMENT OF NON-EXECUTIVE DIRECTORS

The Board is delighted to announce that following Mr. Hu and Mr. Geng's resignations, the Board appointed Mr. GAO Jianming (高建明, "**Mr. Gao**") and Ms. YI Lin (易琳, "**Ms. Yi**") as non-executive Directors with effect from August 18, 2025.

Set out below are the biographical details of Mr. Gao:

Mr. Gao, aged 58, currently serves as chairman of Shanghai Homsun Equity Investment Fund Management Co., Ltd. (上海弘信股權投資基金管理有限公司), and also a shareholder of Naturade Health Technology Co., Ltd. (奈瑞兒健康科技有限公司) and holds a concurrent position as an independent non-executive director of Softcare Limited. Mr. Gao has over 30 years of experience in capital markets, investment management and corporate management.

In addition, Mr. Gao has worked at the finance department of Shanghai University of Finance and Economics (上海財經大學), and held several directorships in the listed companies: (i) Guangdong Keda Mechanical Electrical Co., Ltd. (廣東科達機電股份有限公司) (now known as Keda Industrial Group Co., Ltd. (科達製造股份有限公司)), (SH: 600499; SWX:KEDA); and (ii) Guangzhou Haozhi Industrial Co., LTD (廣州市昊志機電股份有限公司), (SZ: 300503).

Mr. Gao obtained his bachelor's degree in economics in July 1985 and his master's degree in economics in January 1988 from the Shanghai University of Finance and Economics (上海財經大學) in the PRC. Mr. Gao also obtained a doctor's degree in political economy from Fudan University (復旦大學) in the PRC in July 2002.

Set out below are the biographical details of Ms. Yi:

Ms. Yi, aged 43, currently serves as a partner at Beijing Defu Yue'an Investment Consultancy Limited (北京德福悅安投資顧問有限公司) ("**Defu Capital**"). She has nearly 20 years of experience in investment and financing, investor relations, and financial management within China's healthcare industry, along with an extensive network of resources in the medical industry.

DeFu Capital, where Ms. Yi is based, has invested in or acquired healthcare companies such as Jinxin Fertility (HKEX:1951), Gaush Meditech (HKEX:2407), Biokin Pharmaceutical (SH:688506), Easton Biopharmaceuticals (SH:688513), and Zylox-Tonbridge Medical (HKEX:2190).

Ms. Yi previously worked at PricewaterhouseCoopers Zhong Tian LLP (普華永道中天會計師事務所), where she was responsible for auditing and assurance services.

Ms. Yi obtained her bachelor's degree in literature from University of International Business and Economics (對外經濟貿易大學) in the PRC in July 2006. She also obtained her Master of Business Administration (MBA) degree from Guanghua School of Management, Peking University (北京大學光華管理學院) in the PRC in July 2016.

The term of Mr. Gao and Ms. Yi's services as non-executive Directors are for three years commencing today and is subject to retirement and re-election at the annual general meetings of the Company pursuant to the articles of association of the Company. Mr. Gao and Ms. Yi will not receive any remuneration in connection with their role as non-executive directors of the Company under the terms of this agreement.

The two new Directors will bring fresh momentum to the Group's development with their extensive experience in capital markets and industry expertise.

As at the date of this announcement and save as disclosed above, Mr. Gao and Ms. Yi confirm that they did not have any relationship with any director, senior management, chief executive, substantial shareholder or controlling shareholder of the Company and hold no other position within the Company and other members of the Group. Within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), Mr. Gao and Ms. Yi also confirm that they do not have and deemed to have any interest in the shares or underlying shares of the Company or associated corporations and save as disclosed above, they have not held any directorship in any listed companies in Hong Kong or other jurisdictions currently or in the past three years, nor do they hold any other major appointments or professional qualifications. Mr. Gao and Ms. Yi confirm that, there is no other matter that needs to be brought to the attention of the Shareholders or the Stock Exchange and there is no other information which is required to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board would like to take this opportunity to welcome Mr. Gao and Ms. Yi in joining the Board.

CHANGES IN COMPOSITION OF THE REMUNERATION COMMITTEE

Following the resignation of Mr. Hu and the appointment of Mr. Gao, Mr. Gao has been appointed as a member of the remuneration committee of the Company in place of Mr. Hu, with effect from August 18, 2025.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Beauty Farm Medical and Health Industry Inc.
Li Yang
Chairman and executive Director

Hong Kong, August 18, 2025

As at the date of this announcement, the Board comprises Mr. Li Yang as Chairman and executive Director, Mr. Lian Songyong as Vice Chairman and executive Director, Ms. Li Fangyu, Mr. Gao Jianming and Ms. Yi Lin as non-executive Directors and Mr. Fan Mingchao, Mr. Liu Teng and Mr. Jiang Hua as independent non-executive Directors.